TIDMAVCT

RNS Number : 8219K

Avacta Group PLC

26 September 2016

26 September 2016

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Notice of Results

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, will announce its financial results for the year ended 31 July 2016 on Monday, 17 October 2016.

ENDS

Notes to Editors

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                   Tel: +44 (0) 844 414 0452 
  Alastair Smith, Chief Executive    www.avacta.com 
  Officer 
  Tony Gardiner, Chief Financial 
  Officer 
 finnCap Ltd                        Tel: +44 (0) 207 220 0500 
  Geoff Nash / Giles Rolls           www.finncap.com 
  - Nominated Adviser 
  Tim Redfern / Alice Lane 
  - Corporate Broking 
 WG Partners                        Tel: +44 (0) 203 705 9318 
  David Wilson                       Tel: +44 (0) 203 705 9217 
  Nigel Barnes                       www.wgpartners.co.uk 
  Claes Spang 
 FTI Consulting (Financial          Tel: +44 (0) 203 727 1000 
  Media and IR)                      avacta@fticonsulting.com 
  Simon Conway / Natalie 
  Garland-Collins

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.

Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORSEUFSMFMSEFU

(END) Dow Jones Newswires

September 26, 2016 06:21 ET (10:21 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avacta Charts.